Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on NeoGenomics (NASDAQ:NEO) and lowered the price target from $18 to $16.
October 24, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on NeoGenomics and lowered the price target from $18 to $16.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on NeoGenomics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100